Skip to main content

March 2016, Vol 9, Seventh Annual Payers' Guide

Bendeka (Bendamustine Hydrochloride): Rapid-Infusion Formulation Approved for Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphomas

Lisa A. Raedler, PhD, RPh

Alecensa (Alectinib), an Oral Tyrosine Kinase Inhibitor, Approved for Metastatic Non–Small-Cell Lung Cancer with ALK Mutation

Toujeo (Insulin Glargine) U-300 Approved to Improve Glycemic Control in Adults with Type 1 and Type 2 Diabetes

Onivyde (Irinotecan Liposome Injection) a New Treatment Option for Patients with Metastatic Pancreatic Cancer

Lisa A. Raedler, PhD, RPh

Keytruda (Pembrolizumab) First PD-1 Inhibitor Approved for the Treatment of Patients with Metastatic Non–Small-Cell Lung Cancer Expressing PD-L1

Lisa A. Raedler, PhD, RPh

Imlygic (Talimogene Laherparepvec): First Oncolytic Viral Therapy for the Treatment of Patients with Recurrent Melanoma

Lisa A. Raedler, PhD, RPh

Finacia Foam (Azelaic Acid) the Newest Topical Treatment FDA Approved for the Treatment of Inflammatory Lesions of Rosacea

Ibrance (Palbociclib): First CDK4 and CDK6 Inhibitor Approved for Postmenopausal Women with Metastatic Breast Cancer

Lisa A. Raedler, PhD, RPh

FDA Approvals, Payers' Guide

The Year 2015 Had Highest Number of Drug Approvals in the New Millennium, but with Controversy

Gary M. Owens, MD

FDA Approvals, Payers' Guide

FDA Approvals of Brand-Name Prescription Drugs in 2015

Page 2 of 5
Results 11 - 20 of 43